Autonomic cerebral vascular response to sildenafil in diabetic patient

Diabetology & Metabolic Syndrome

Ahmed M Al-Mudhaffer¹  Najah R Hadi¹  Akeel AMH Zwain²  Fadhil G Al-Amran³ 

[1] Department of Pharmacology, postal code 474, Medical college Kufa University, Kufa Najaf street, Najaf, Iraq;Department of Cardiovascular Physiology, postal code 474, Medical college Kufa University, Kufa Najaf street, Najaf, Iraq;FRCS, FACS, Department of Surgery, postal code 474, Medical college Kufa University, Kufa Najaf street, Najaf, Iraq

关键词: sildenafil;    breath holding-hyperventilation test transcranial Doppler;    stroke;    cerebrovascular reactivity;   

Others  :  817457
DOI  :  10.1186/1758-5996-4-2

 received in 2011-03-11, accepted in 2012-01-27,  发布年份 2012

【 摘 要 】

Background

Erectile dysfunction is a common problem in type 2 diabetic patients who are at higher risk of cerebrovascular events, and it's recorded with sildenafil, a drug which is primarily used for erectile dysfunction.

Objectives

We tested the hypothesis whether or not sildenafil modulates cerebrovascular reactivity (CVR) in patients with type 2 diabetes mellitus.

Methods

A total of 35 male participants were enrolled; eighteen with type 2 diabetes mellitus matched with seventeen normal individuals. Transcranial Doppler Ultrasonographic examination (TCD) was performed for all participants to insonate the middle cerebral artery (MCA) through a trans-temporal window. CVR was assessed by using breath holding (BH)-hyperventilation (HV) test, before and after oral 50 mg sildenafil; recordings were analyzed by using SPSS program version 12.

Results

In normal individuals, sildenafil did not result in statistically significant change in breath holding index (BHI) from 0.91 ± 0.11 to 0.81 ± 0.09 and full range of vasodilatation (FVD) from (59.4% ± 6.3%) to (53.7% ± 4.9%). In diabetic patients, giving sildenafil resulted in significant increase in BHI (from 0.74 ± 0.14 to 1.03 ± 0.14) and FVD (from 60.2% ± 4.96% to 74% ± 4.8%), (p < 0.05).

Conclusion

Sildenafil significantly improves CVR in type 2 diabetic patients but not in normal subjects.

【 授权许可】

   
2012 Al-Amran et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Michael GH, Stephen PM: Cerebral vasoreactivity; cerebrovascular ultrasound. 2001, Chapter 23(B.Widder):324-333.
• [2]Lavi S, Egbarya R, Lavi R, Jacob G: Role of nitric oxide in the regulation ofcerebral blood flow in humans: chemoregulation versus mechanoregulation. Circulation 2003, 107:1901-1905.
• [3]Johnston AJ, Steiner LA, Gupta AK, Menon DK: Cerebral oxygen vasoreactivity and cerebral tissue oxygen reactivity. Br J anaesth 2003, 90(6):774-786.
• [4]Markus HS, Harrison MJG: Estimation of cerebrovascular reactivity using transcranial Doppler, including the use of breath-holding as the vasodilatory stimulus. Stroke 1992, 668-673.
• [5]Makimattila S, Malmberg-Ceder K, Hakkinen AM, Vuori K, Salonen O, Summanen P, Yki-Jarvinen H, Kaste M, Heikkinen S, Lundbom N, Roine RO: Brain metabolic alterations in patients with type 1 diabetes-hyperglycemia-induced injury. J Cereb Blood Flow, Metab 2004, 24:1393-1399.
• [6]Cheitlin MD, Hutter AM Jr, Brindis RG, Ganz P, Kaul S, Russell RO Jr, Zusman RM: Use of sildenafil (Viagra) in patients with cardiovascular disease. Journal of the American College of Cardiology 1999, 33(1):273-82.
• [7]Naylor AM: Endogenous neurotransmitters mediating penile erection. Br J Urol 1998, 81:424-431.
• [8]Benet AE, Melman A: The epidemiology of erectile dysfunction. Urol Clin North Am 1995, 22:699.
• [9]Rosengarten B, Schermuly RT, Voswinckel R, Kohstall MG: Sildenafil Improves Dynamic Vascular Function in the Brain: Studies in Patients with Pulmonary Hypertension. Cerebrovasc Dis 2006, 21:194-200.
• [10]Kruuse C, Jacobsen TB, Thomsen LL, Hasselbalch SG, Frandsen EK, Dige-Petersen H, Olesen J: Effects of the non-selective phosphodiesterase inhibitor pentoxifylline on regional cerebral blood flow and large arteries in healthy subjects. Eur J Neurol 2000, 7:629-638.
• [11]Diomedi M, Sallustio F, Rizzato B, Ferrante F: Sildenafil increases cerebrovascular reactivity: A transcranial Doppler study. NeurologyVolume 2005, 65(6):919-921.
• [12]Victor PM, Hulst V, Baalen J, Kool LS: Renal Artery Stenosis. Endovascular Flow Wire Study for Validation of Doppler U.S. Radiology 1996, 200:165-168.
• [13]Eicke BM, Buss E, Bähr RR, Hajak G, Paulus W: Influence of Acetazolamide and CO2 on Extracranial Flow Volume and Intracranial Blood Flow Velocity. Stroke 1999, 30:76-80.
• [14]Arnavaz A, Aurich A, Weibenborn K, Hartmann U, Emrich HM: Schneider U. Effects of sildenafil (Viagra_) on CBF velocity: a pilot study. Psychiatry Res 2003, 122:207-209.
• [15]Wei HM, Shah AJ, Tse J, Chi OZ, Weiss HR: Cyclic GMP phosphor-diesterase inhibition does not alter cerebral oxygen consumption. Neurochem Res 1996, 21:41-46.
• [16]Desouza C, Parulkar A, Lumpkin D, Akers D, Fonseca VA: Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. Diabetes Care 2002, 25:1336-1339.
• [17]Katz SD, Balidemaj K, Homma S, Wu H, Wang J, Maybaum S: Acute type 5-phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilatation in patients with chronic heart failure. J Am Coll Cardiol 2000, 36:845-51.
• [18]Kimura M, Higashi Y, Hara K, Noma K, Sasaki S, Nakagawa K, Goto C, Oshima T, Yoshizumi M, Chayama K: PDE5 inhibitor sildenafil citrate augments endothelium-dependent vasodilatation in smokers. Hypertension 2003, 41:1106-1110.
• [19]Robinson SD, Ludlam CA, Boon NA, Newby DE: Phosphodiesterase type 5 inhibition does not reverse endothelial dysfunction in patients with coronary heart disease. Heart 2006, 92(2):170-176.
• [20]Dishy V, Harris PA, Pierce R, Prasad HC, Sofowora G, Bonar HL, Wood HA, Stein CM: Sildenafil does not improve nitric oxide-mediated endothelium-dependent vascular responses in smokers. British Journal of Clinical Pharmacology 2004, 57(2):209-212.
• [21]Gilbert P, Tremblay J, Thorin E: Endothelium-derived endothelin-1 reduces cerebral artery sensitivity to nitric oxide by a protein kinase C-independent pathway. Stroke 2001, 32:2351-5.
• [22]Fisher PW, Salloum F, Das A, Hyder H, Kukreja RC: Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation 2005, 111:1601-1610.
• [23]Lincoln TM: Cyclic GMP and mechanisms of vasodilatation. Pharmacol Ther 1989, 41:479-502.